Provided by Tiger Trade Technology Pte. Ltd.

Enliven Treateutics

40.98
+0.35000.86%
Post-market: 40.980.00000.00%16:38 EDT
Volume:1.00M
Turnover:41.43M
Market Cap:3.00B
PE:-24.46
High:42.06
Open:41.00
Low:40.29
Close:40.63
52wk High:62.32
52wk Low:14.79
Shares:73.27M
Float Shares:61.73M
Volume Ratio:0.68
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6753
EPS(LYR):-1.8300
ROE:-15.31%
ROA:-11.00%
PB:3.35
PE(LYR):-22.39

Loading ...

TD Cowen Remains a Buy on Enliven Therapeutics (ELVN)

TIPRANKS
·
Oct 08

Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial

MT Newswires Live
·
Oct 07

Enliven Therapeutics Announces FDA Alignment on Enable-2 Phase 3 Trial Design for Relcobatinib (Elvn-001) in Previously Treated Chronic Myeloid Leukemia

THOMSON REUTERS
·
Oct 07

Enliven Therapeutics - on Track to Initiate Enable-2 Phase 3 Trial Before Year-End 2026

THOMSON REUTERS
·
Oct 07

Enliven Therapeutics Director Garland J. Scott Disposes of $606,719 in Common Shares

Reuters
·
Oct 06

Enliven initiated with an Overweight at Morgan Stanley

TIPRANKS
·
Oct 02

Enliven Therapeutics, Inc. : JP Morgan Initiates Coverage with Overweight Rating; Target Price $75

THOMSON REUTERS
·
Oct 01

Enliven Therapeutics CMO Helen Louise Collins Disposes of USD 250,000 in Common Shares

Reuters
·
Sep 22

Enliven Therapeutics Management to Attend Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Sep 04

Enliven Therapeutics to Present Phase 1 Enable Trial Data for ELVN-001 in CP-CML at SOHO 2026

Reuters
·
Sep 01

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (Soho) 2026 Annual Meeting

THOMSON REUTERS
·
Sep 01

Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)

TIPRANKS
·
Aug 24

Enliven Therapeutics CMO Helen Louise Collins Reports Disposal of 5,000 Common Shares Worth $293,612.17

Reuters
·
Aug 20

Enliven Therapeutics, Inc. : Mizuho Raises Target Price to $73 from $62

THOMSON REUTERS
·
Aug 18

Enliven initiated with an Outperform at William Blair

TIPRANKS
·
Aug 18

Enliven Therapeutics, Inc. : William Blair Initiates Coverage with Outperform Rating

THOMSON REUTERS
·
Aug 18

U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies

Reuters
·
Aug 17

Enliven Therapeutics (ELVN) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
Aug 13

Enliven Therapeutics Director Mika K. Derynck Sells USD 9.56 Million in Common Shares

Reuters
·
Aug 07

Stifel Nicolaus Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)

TIPRANKS
·
Aug 06